|
2025-06-10 |
2025-06-10 |
VP
Vente planifiée
|
Nichols Christian Todd
SVP, Chief Commercial Officer
Dirigeant
|
3 334
-3.7%
31,09
103 654 USD
|
3 334
-3.7%
|
31,09
|
103 654 USD
|
|
|
2025-06-10 |
2025-06-09 |
VP
Vente planifiée
|
Nichols Christian Todd
SVP, Chief Commercial Officer
Dirigeant
|
3 333
-3.6%
31,95
106 489 USD
|
3 333
-3.6%
|
31,95
|
106 489 USD
|
|
|
2025-02-28 |
2025-02-28 |
VP
Vente planifiée
|
Parisi Samuel Joseph
VP, Finance (Interim PAO)
Dirigeant
|
1 938
-20.1%
34,00
65 892 USD
|
1 938
-20.1%
|
34,00
|
65 892 USD
|
|
|
2025-02-25 |
2025-02-25 |
VP
Vente planifiée
|
Parisi Samuel Joseph
VP, Finance (Interim PAO)
Dirigeant
|
3 743
-32.7%
35,26
131 978 USD
|
3 743
-32.7%
|
35,26
|
131 978 USD
|
|
|
2025-02-20 |
2025-02-20 |
VP
Vente planifiée
|
Parisi Samuel Joseph
VP, Finance (Interim PAO)
Dirigeant
|
1 327
-14.7%
35,69
47 361 USD
|
1 327
-14.7%
|
35,69
|
47 361 USD
|
|
|
2025-02-14 |
2025-02-13 |
VP
Vente planifiée
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Dirigeant
|
108 833
-65.3%
36,02
3 920 001 USD
|
108 833
-65.3%
|
36,02
|
3 920 001 USD
|
|
|
2025-02-14 |
2025-02-13 |
VP
Vente planifiée
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Dirigeant
|
35 586
-17.6%
34,02
1 210 696 USD
|
35 586
-17.6%
|
34,02
|
1 210 696 USD
|
|
|
2025-02-14 |
2025-02-12 |
VP
Vente planifiée
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Dirigeant
|
33 108
-36.4%
33,27
1 101 470 USD
|
33 108
-36.4%
|
33,27
|
1 101 470 USD
|
|
|
2025-02-14 |
2025-02-12 |
VP
Vente planifiée
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Dirigeant
|
171 813
-65.4%
32,69
5 616 808 USD
|
171 813
-65.4%
|
32,69
|
5 616 808 USD
|
|
|
2025-01-31 |
2025-01-30 |
VP
Vente planifiée
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Dirigeant
|
100 918
-69.5%
32,05
3 234 382 USD
|
100 918
-69.5%
|
32,05
|
3 234 382 USD
|
|
|
2024-12-09 |
2024-12-09 |
VP
Vente planifiée
|
LAURENCIN CATO T
Administrateur non-exécutif
|
2 691
-10.5%
31,85
85 708 USD
|
2 691
-10.5%
|
31,85
|
85 708 USD
|
|
|
2024-12-09 |
2024-12-09 |
VP
Vente planifiée
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Dirigeant
|
61 151
-56.2%
32,07
1 961 406 USD
|
61 151
-56.2%
|
32,07
|
1 961 406 USD
|
|
|
2024-12-05 |
2024-12-05 |
VP
Vente planifiée
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Dirigeant
|
9 221
-13.4%
31,50
290 462 USD
|
9 221
-13.4%
|
31,50
|
290 462 USD
|
|
|
2024-12-04 |
2024-12-04 |
VP
Vente planifiée
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Dirigeant
|
14 349
-17.2%
30,77
441 550 USD
|
14 349
-17.2%
|
30,77
|
441 550 USD
|
|
|
2024-11-27 |
2024-11-27 |
VP
Vente planifiée
|
Nichols Christian Todd
SVP, Chief Commercial Officer
Dirigeant
|
5 208
-7.9%
29,15
151 813 USD
|
5 208
-7.9%
|
29,15
|
151 813 USD
|
|
|
2024-11-12 |
2024-11-11 |
VP
Vente planifiée
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Dirigeant
|
58 996
-41.5%
30,08
1 774 576 USD
|
58 996
-41.5%
|
30,08
|
1 774 576 USD
|
|
|
2024-11-06 |
2024-11-06 |
VP
Vente planifiée
|
Hopkinson Craig C.
EVP R&D, Chief Medical Officer
Dirigeant
|
10 471
-9.5%
29,53
309 169 USD
|
10 471
-9.5%
|
29,53
|
309 169 USD
|
|
|
2024-03-18 |
2024-03-18 |
VP
Vente planifiée
|
Nichols Christian Todd
SVP, Chief Commercial Officer
Dirigeant
|
10 417
-13.6%
28,10
292 740 USD
|
10 417
-13.6%
|
28,10
|
292 740 USD
|
|
|
2024-02-27 |
2024-02-27 |
V
Vente
|
Parisi Samuel Joseph
VP, Finance (Interim PAO)
Dirigeant
|
2 559
-24.9%
29,65
75 874 USD
|
2 559
-24.9%
|
29,65
|
75 874 USD
|
|
|
2024-02-16 |
2024-02-15 |
VP
Vente planifiée
|
LAURENCIN CATO T
Administrateur non-exécutif
|
2 690
-15.1%
31,85
85 677 USD
|
2 690
-15.1%
|
31,85
|
85 677 USD
|
|
